Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 421-426

  Rubatt, Jennifer M ^a   Darcy, Kathleen M ^b   Tian, Chunqiao ^b   Muggia, Franco ^c   Dhir, Rajiv ^d   Armstrong, Deborah K ^e   Bookman, Michael A ^f   Niedernhofer, Laura J ^g,h   Deloia, Julie ⁱ   Birrer, Michael ^j   Krivak, Thomas Carl ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ GEORGE WASHINGTON UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Biomarker; DNA repair; Ovarian cancer; Platinum resistance; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PARAFFIN EMBEDDING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859570977     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.008     Document Type: Article

References (35)

1. Howlader N, Noone AM, KrapchoM, Neyman N, Aminou R,WaldronW, et al, editors. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011 http://seer.cancer.gov/csr/1975-2008/. based on November 2010 SEER data submission, posted to the SEER web site.
2. HoskinsWJ, Bundy BN, Thigpen JT,Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66. (Pubitemid 23001322)
3. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9 (discussion 979-80).
4. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20. (Pubitemid 13158699)
5. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84:399-403. (Pubitemid 34211865)
6. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7(Suppl. 5):20-8.
7. Winter III WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7. (Pubitemid 47372600)
8. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxidity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
9. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 2009;8:48.
10. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010;31:961-7.
11. Volker M, Moné MJ, Karmaker P, van Hoffen A, Schul W, Vermeulen W, et al. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2001;8:213-24. (Pubitemid 32772919)
12. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24: 5776-87. (Pubitemid 38787963)
13. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5. (Pubitemid 351413906)
14. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-44. (Pubitemid 28537769)
15. Handra-Luca A,Hernandez J,Mountzios G, Taranchno E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:3855-9. (Pubitemid 47037591)
16. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
17. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-9. (Pubitemid 46359630)
18. Steffensen KD, Waldstrom M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:820-5.
19. Reed E, DabholkarM, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F, et al. Evidence for in the appearance ofmRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep 2000;7:1123-8.
20. Stadlmann S, Dirnhofer S, Güth U, Thies S, Singer G. ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecol Oncol 2008;108: 252-3. (Pubitemid 350299428)
21. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50: 211-9. (Pubitemid 41427896)
22. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 2009;69:6831-8.
23. Armstrong DK, Bundy B,Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
24. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-25.
25. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 2008;26: 3598-606.
26. Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick-Bruton F, et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol 1998;13:987-92. (Pubitemid 28506069)
27. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20:645-52. (Pubitemid 30240614)
28. Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 2008;18:702-10. (Pubitemid 352020157)
29. Lin K, Ye D,Xie X. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:1007-12.
30. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
31. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20. (Pubitemid 28376643)
32. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007;25:5172-9.
33. KimHS, KimMK, ChungHH, KimJW, ParkNH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treatedwith taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009;113:264-9.
34. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010;10:54-61.
35. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25: 4528-35. (Pubitemid 350035308)